A Uniqe Antilipidemic Drug — Probucol
Author:
- Akira YamamotoAYAkira Yamamoto
- 1 January 2008
- journal article
- Published by Japan Atherosclerosis Society in Journal of Atherosclerosis and Thrombosis
- Vol. 15 (6) , 304-305
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Influence of the HDL receptor SR-BI on atherosclerosisCurrent Opinion in Lipidology, 1999
- Relation of High TG–Low HDL Cholesterol and LDL Cholesterol to the Incidence of Ischemic Heart DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- The effect of probucol on femoral atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PQRST)The American Journal of Cardiology, 1994
- ProbucolDrugs, 1989
- Beyond CholesterolNew England Journal of Medicine, 1989
- Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesionsThe American Journal of Cardiology, 1988
- Probucol inhibits oxidative modification of low density lipoprotein.Journal of Clinical Investigation, 1986
- Effects of probucol on homozygous cases of familial hypercholesterolemiaAtherosclerosis, 1983
- ProbucolDrugs, 1978
- Preferential Utilization of Free Cholesterol From High-Density Lipoproteins for Biliary Cholesterol Secretion in ManScience, 1978